CN115645381B - Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof - Google Patents
Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof Download PDFInfo
- Publication number
- CN115645381B CN115645381B CN202211287768.2A CN202211287768A CN115645381B CN 115645381 B CN115645381 B CN 115645381B CN 202211287768 A CN202211287768 A CN 202211287768A CN 115645381 B CN115645381 B CN 115645381B
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- stirring
- solvent
- levosalbutamol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 238000013268 sustained release Methods 0.000 title claims abstract description 26
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 26
- 229940041682 inhalant solution Drugs 0.000 title claims abstract description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title description 6
- OWNWYCOLFIFTLK-YDALLXLXSA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydron;chloride Chemical compound Cl.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 OWNWYCOLFIFTLK-YDALLXLXSA-N 0.000 claims abstract description 80
- 229940087642 levalbuterol hydrochloride Drugs 0.000 claims abstract description 36
- 239000002105 nanoparticle Substances 0.000 claims abstract description 29
- 239000002131 composite material Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 9
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 8
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 8
- 229920002258 tannic acid Polymers 0.000 claims abstract description 8
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 8
- 229940033123 tannic acid Drugs 0.000 claims abstract description 8
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000003708 ampul Substances 0.000 claims description 12
- 238000011146 sterile filtration Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000012065 filter cake Substances 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- -1 L-lactic acid-ethylene glycol Chemical compound 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000012859 sterile filling Methods 0.000 claims description 6
- YCLSOMLVSHPPFV-UHFFFAOYSA-N 3-(2-carboxyethyldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSCCC(O)=O YCLSOMLVSHPPFV-UHFFFAOYSA-N 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 45
- 229940079593 drug Drugs 0.000 abstract description 22
- 238000011068 loading method Methods 0.000 abstract description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 6
- 229910052742 iron Inorganic materials 0.000 abstract description 4
- 230000000536 complexating effect Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 38
- 208000006673 asthma Diseases 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 22
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 17
- 229950008204 levosalbutamol Drugs 0.000 description 16
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 241000700198 Cavia Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000002502 liposome Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002345 respiratory system Anatomy 0.000 description 8
- 229960002052 salbutamol Drugs 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000000889 atomisation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000010579 first pass effect Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 4
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
- 229960000707 tobramycin Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 208000024696 nocturnal asthma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a levalbuterol hydrochloride aerosol inhalation solution sustained release agent and a preparation method thereof, mainly comprising the following components: the preparation method comprises the steps of compound nano-particles of levalbuterol hydrochloride, an isotonic agent, a pH regulator and a solvent. The levalbuterol hydrochloride composite nano-particle is obtained by complexing a composite network of iron and tannic acid and the encapsulated levalbuterol hydrochloride dimer, has long-term and excellent stability, can not be released prematurely, has good biocompatibility, and can also meet the current loading requirements of medicines. Inhalation administration can improve patient compliance and also alleviate or avoid some adverse drug reactions.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a levalbuterol hydrochloride aerosol inhalation solution sustained release agent and a preparation method thereof.
Background
Salbutamol (Albuterol) is an adrenergic beta receptor agonist, which can bind to beta 2 receptor on human respiratory smooth muscle, increase the concentration of cyclic adenosine monophosphate (cAMP) in cells, and the cAMP further activates protein kinase A to phosphorylate muscle protein, reduce the concentration of calcium ions in cells and relax bronchus smooth muscle. Increased cAMP concentrations also inhibit the release of mast cell inflammatory mediators. Salbutamol is a racemate, wherein only the levorotatory body has the effect of dilating bronchial smooth muscle, and the dextrorotatory body has no effect, but can be combined with beta receptor to generate side effects such as headache, dizziness, palpitation, finger tremor and the like. The levosalbutamol is a single optical isomer of the salbutamol, the drug effect is 80 times of that of the salbutamol, the side effect is reduced, the curative effect is further improved, the same curative effect can be produced by only 1/4 of the dosage of the raceme of the levosalbutamol, and the effect is better than that of the raceme at 1/2 of the dosage. In Chronic Obstructive Pulmonary Disease (COPD), the pro-inflammatory response of levalbuterol is weaker than albuterol. The traditional Chinese medicine has obvious bronchiectasis effect, and is the first choice medicine for clinically treating bronchial asthma, asthmatic bronchitis, bronchospasm of emphysema patients, acute asthma attack and the like at present.
Levalbuterol currently relieves asthma by oral ingestion, intravenous injection and aerosol inhalation. The average retention time of the whole body of the levalbuterol is 3 hours, the elimination half-life period is 3-4 hours when the levalbuterol is taken orally, the bioavailability is about 30-50% when the levalbuterol is taken orally, and the bioavailability is reduced by 14.8%. The biological half-life of levalbuterol is short, so frequent administration is required to maintain bronchodilatory effect, and in order to use levalbuterol for treating nocturnal asthma, development of a sustained-release long-acting levalbuterol dosage form has been receiving extensive attention, and many researches have focused on developing a sustained-release long-acting oral levalbuterol form. The atomized inhalation has the advantages of faster curative effect, strong targeting, avoidance of first pass effect, less administration dosage, capability of reducing toxic and side effects of the drug on other tissues of the whole body, and is the safest and effective method for treating asthma at present, and is proposed by WHO global asthma prevention and treatment as the first choice therapy. Inhaled aerosolized β2 receptor agonists have been used in clinical treatment of severe acute bronchial asthma attacks, however, inhaled albuterol also requires frequent dosing due to the faster pharmacokinetic processes. The medicine takes effect 5-15 min after inhalation, the bronchiectasis time reaches 6 hours, the routine inhalation amount of adults is 0.25-0.5 mg/time, and the medicine is taken as required. The asthma attack has circadian rhythm, the best time of the lung function condition is 4 pm, and the time of the lung function condition is the weakest in the early morning, in order to ensure that the anti-asthma medicine still has effective dose to relieve asthma symptoms in the patient when the asthma attack is in the early morning, the development of the long-acting anti-asthma medicine which can be taken in the evening before day and can exert the medicine effect until the next morning is necessary, and the long-acting inhaled beta 2 receptor agonist (such as salmeterol, formoterol) can effectively control night asthma which is insufficient to control the anti-inflammatory medicine. In addition, sustained release theophylline and controlled release oral β2 receptor agonists (such as oral controlled release salbutamol and terbutaline) are also effective. Studies have shown that long-acting inhaled β2 receptor agonists are superior to other long-acting bronchodilators. Long-acting inhaled β2 receptor agonists are the first option for the treatment of nocturnal asthma in addition to anti-inflammatory drugs and other standard control measures such as environmental quality control. Because the mode of aerosol inhalation of the levosalbutamol is superior to oral intake, the development of a long-acting preparation of the aerosol inhalation of the levosalbutamol is also necessary, and the long-acting preparation of the aerosol inhalation of the levosalbutamol can not only exert the advantages of aerosol inhalation, but also be beneficial to the aerosol inhalation of the levosalbutamol for treating night asthma. The levalbuterol needs a proper carrier for pulmonary delivery, so that the levalbuterol inhaled by atomization not only can play a role in timely relieving asthma, but also can continuously exist at an action part for a long time and play a drug effect through the slow release effect of the carrier.
The traditional oral dosage form has large dosage, can not directly act on the affected part, needs to enter the circulatory system to act on the affected part through the first pass effect of the liver, has slower effect, and limits the medication of patients to a certain extent. The injection needs to act on the affected part through a circulatory system, so that the medicine is distributed more in other tissues, the toxic and side effects of the medicine are increased, and meanwhile, the problem of pain at the administration part and poor patient compliance exists in the administration of the injection. The aerosol inhalation solution preparation can be used as a respiratory tract or lung administration preparation, can directly act on a patient part, can improve the administration concentration of the respiratory tract or the lung, has quick response, avoids the first pass effect of the liver, reduces the administration dosage of the medicine, improves the bioavailability of the medicine, reduces the distribution of the medicine in other tissues, and reduces side effects. The pulmonary inhalation preparation refers to a preparation which can exert systemic or local effects through deep respiratory tract, cavity tract, mucosa and the like after being administered by a special device. Such dosage forms currently in clinical use mainly include metered dose inhalation aerosols (metered dose inhaler, MDI), dry powder inhalants (dry powder inhaler, DPI) and aerosol inhalants (nebulizer). The aerosol inhalation is an administration method for preparing the medicine into tiny fog particles or fog drops (the diameter is generally smaller than 5 mu m) to suspend in the gas by utilizing the negative pressure space of the aerosol inhaler, so that the medicine is humidified and inhaled into the respiratory tract to achieve the effects of moistening mucous membrane, diminishing inflammation, eliminating phlegm, relieving spasm, relieving asthma and the like. The drug is delivered through the lung in a non-invasive way, not only can provide local lung effect, but also has higher system bioavailability, can avoid first pass metabolism, can exert the treatment effect more quickly, and the alveoli provide huge available surface area.
Pulmonary inhalation administration is another more attractive route of administration in addition to oral, injectable administration. From the action time, the medicine can be rapidly eliminated in the lung and has short half-life. Clinical studies on pulmonary drug delivery currently show that due to the unique physiological characteristics of the lung (large blood flow and abundant capillaries), multiple drug delivery is mostly required and patient compliance is poor. Therefore, the development of a lung sustained-release preparation capable of improving the curative effect of the drug and improving the use compliance of the drug is needed. The preparation can avoid the clearance of lung macrophages, and a nano preparation which resides in the lung for a plurality of weeks (the mechanism of ensuring that the nano preparation is not exhaled is inhaled after the nano particles are agglomerated to a micron-sized agglomeration body) is a very potential lung slow release carrier. The nano-carrier for pulmonary administration mainly comprises nano-liposome, nano-micelle, solid lipid nanoparticle, microsphere, nanocrystal, nanoemulsion and the like.
Patent CN110898039 a discloses a levalbuterol hydrochloride solution preparation for inhalation and a preparation method thereof. A levalbuterol hydrochloride solution formulation for inhalation comprising: levalbuterol hydrochloride, and/or hydrates thereof; osmotic pressure regulator; a pH regulator; the stabilizer and the solvent the levosalbutamol hydrochloride solution preparation for inhalation has the advantages of high stability, reliable quality, good safety, long storage time, no need of nitrogen filling, simplified preparation process, reduced requirements on production equipment, simplicity, easy operation, low production cost and easy industrialized production.
Patent CN111228243 a discloses a tobramycin liposome for aerosol inhalation, which consists of the following components: tobramycin 0.1-15.0%, phospholipid 0.5-36.0%, stabilizer 0.05-20.0%, charge modifier 0.01-10.0%, antioxidant 0.01-5.0%, organic phase medium 5.0-50.0%, and water phase medium for the rest; compared with oral administration, the tobramycin liposome for aerosol inhalation can directly transfer the medicine to the respiratory tract, has quick absorption and quick action, and can improve the medicine concentration of the respiratory tract; the bioavailability and stability are high, and the safety is good; the preparation process is simple, easy to prepare and reasonable, and the performance is stable, thereby creating conditions for realizing industrial productization.
Generally, there are two strategies for constructing drug delivery systems. The traditional method is to wrap the hydrophobic drug by means of hydrophobic interactions, electrostatic interactions, hydrogen bonding, pi-pi stacking and the like. Because of the simplicity of operation, this method is widely used in constructing drug delivery systems and in therapy. However, this relatively weak physical interaction may lead to premature release of the drug delivery system in the blood circulation in the body following administration. At the same time, it is also limited by low drug loading. Another strategy is to chemically couple the drug directly to the carrier to prepare prodrug nanoparticles. The prodrug nanoparticle has the advantages of high drug loading, low toxic and side effects, good stability, reduction of undesirable premature release and the like. Compared with liposome, the microsphere has more stable physical and chemical behaviors in vivo and in vitro, can achieve slow release effect, has better pharmacological activity, and is beneficial to delivering drugs to the lung. Therefore, the application of the nano levosalbutamol hydrochloride particles to the aerosol inhalation solution sustained release preparation is developed, the drug effect is greatly improved, and the drug release time and the stability are further improved.
Disclosure of Invention
In view of the above-mentioned drawbacks in the prior art, the present invention aims to provide a levalbuterol hydrochloride aerosol inhalation solution sustained release agent with longer efficacy and more stability and a preparation method thereof.
Pulmonary administration is a non-invasive mode of administration. Compared with oral administration, the lung has large specific absorption surface area, the alveolar epithelial cell layer is thin (0.1-0.2 μm), the drug permeation distance is short, small molecules can be rapidly absorbed by the body, and the bioavailability is high. In addition, the metabolic enzyme activity of the lung is low, and the degradation effect on protein and polypeptide medicines is small. Compared with injection administration, the lung administration is more convenient, and the patient compliance is high. The lung administration mode can directly deliver the medicine to lung tissues, is particularly suitable for treating lung diseases, and can reduce systemic toxic and side effects. Many current pulmonary modes of administration improve drug biology by encapsulating the drug to produce nanoparticle delivery systems; the preparation has the defects of low utilization rate, serious side effects and the like, but the application of the preparation is still severely limited due to the reasons of complex preparation, poor stability, low drug loading, premature release of the drug and the like. The present inventors have greatly improved the above drawbacks by synthesizing a drug delivery system for metal phenolic networks, which has good stability, drug loading and biocompatibility, and which is synthesized mainly by: firstly preparing the levosalbutamol hydrochloride dimer through oxidation-reduction reaction, then encapsulating the levosalbutamol hydrochloride dimer by using the prepared modified poly (D, L-lactic acid-ethylene glycol) polymer, enhancing the water solubility and improving the stability, and then complexing the complex network of iron and tannic acid and the encapsulated levosalbutamol hydrochloride dimer to obtain the levosalbutamol hydrochloride composite nano-particles. The nanoparticle has long-term and excellent stability, does not release prematurely, has good biocompatibility, and can also meet the current loading requirements.
The technical scheme of the invention is as follows:
the levosalbutamol hydrochloride aerosol inhalation solution sustained release agent mainly comprises the following components in percentage by mass: 0.05 to 0.06 percent of levalbuterol hydrochloride composite nano-particles, 0.2 to 0.9 percent of isotonic agent, 0.001 to 0.005 percent of pH regulator and the balance of solvent.
The preparation method of the levalbuterol hydrochloride composite nano-particles comprises the following steps:
x1, weighing 6-7 g of levosalbutamol hydrochloride, adding the levosalbutamol hydrochloride into 60-70 mL of dichloromethane, stirring for 1-2 h, adding 0.02-0.03 g of 4-dimethylaminopyridine, 0.02-0.03 g of 3, 3-dithiodipropionic acid, 0.5-0.6 g of N, N' -dicyclohexylcarbodiimide, heating to 40-45 ℃ for reflux, stirring for 2-3 d, filtering after the reaction is finished, and drying a filter cake to obtain levosalbutamol hydrochloride dimer;
weighing 0.63-0.65 g of D, L-lactic acid, 0.27-0.30 g of ethylene glycol, 0.1-0.15 g of maleic acid, adding into an ampoule bottle, adding 0.0.3-0.04 g of benzoyl peroxide, 0.01-0.02 g of stannous iso-octoate, vacuumizing the ampoule bottle, drying at 30-35 ℃ for 10-12 h, performing melt polymerization at 140-150 ℃, reacting for 20-24 h, dissolving the mixture into 20-30 mL of chloroform after the reaction is finished, adding into 100-200 mL of ethanol, precipitating, filtering, and vacuum drying a filter cake to obtain maleic anhydride modified polylactic acid;
x3, dissolving 1-1.1 g of the maleic anhydride modified polylactic acid in the step X2 in 5-10 mL of chloroform, slowly dropwise adding 0.2-0.3 g of 1, 4-butanediamine, stirring for 10-20 min at 5-10 ℃, heating to room temperature, stirring for 30-40 min, adding the mixture into 50-100 mL of ethanol after the reaction is finished, stirring, precipitating, filtering, washing a filter cake with water until the pH value is=7-8, and then drying at 35-40 ℃ for 20-24 h to obtain a modified poly (D, L-lactic acid-ethylene glycol) polymer;
x4, weighing 1.5-1.8 g of levosalbutamol hydrochloride dimer, adding 0.125-0.15 g of modified poly (D, L-lactic acid-ethylene glycol) polymer into 5-6 mL of dimethyl sulfoxide, stirring and dissolving, adding 45-54 mL of water, performing ultrasonic dispersion for 1-2 h, continuously adding 2-2.4 mg of tannic acid, 0.5-0.6 mg of ferric chloride, performing ultrasonic dispersion for 1-2 h, centrifuging at 8000-10000 rpm, obtaining lower-layer sediment, and drying to obtain the levosalbutamol hydrochloride composite nano-particles.
The invention also provides a preparation method of the levalbuterol hydrochloride aerosol inhalation solution sustained release agent, which comprises the following steps:
s1, adding 50-80% of the total amount of solvent into a liquid distributor, adding the prescription dose of levalbuterol hydrochloride composite nano particles and an isotonic agent, and stirring until the solvent is completely dissolved;
s2, adding a pH regulator to regulate the pH;
s3, adding the solvent to the full amount, and stirring to uniformly mix the solvent;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into an ampoule with the filling amount of 3mL.
Further, the solvent is purified water, water for injection or sterile water for injection.
Further, the total amount of water is 3 to 4L.
Further, the prescription amount of the levalbuterol hydrochloride composite nano-particles is 4-5 g.
Further, the isotonic agent is one of sodium chloride, magnesium chloride and calcium chloride.
Further, the adding amount of the isotonic agent is 27-30 g.
Further, in the step S1, the stirring temperature of the solvent is controlled to be 15-35 ℃.
Further, the pH regulator is one of hydrochloric acid, sulfuric acid, lactic acid, malic acid, acetic acid, phosphoric acid and citric acid.
Further, the pH value adjusted in the step S2 is 4.5 to 5.5.
Preferably, the pH regulator is one of sulfuric acid or hydrochloric acid.
Compared with the prior art, the invention has the beneficial effects that:
(1) The inventor greatly improves the existing defects by synthesizing a metal phenolic network drug delivery system, and the drug delivery system of the levalbuterol hydrochloride composite nano-particles has good stability, drug loading capacity and biocompatibility;
(2) Compared with oral administration, the medicine can be directly transferred to respiratory tract by using an aerosol inhalation technology, has the advantages of quick absorption, quick action, high concentration of the medicine in the respiratory tract, improved curative effect, minimized systemic exposure, reduced systemic toxic and side effects, avoidance of first pass effect of liver, high bioavailability and reduced medicine dosage; compared with injection administration, inhalation administration can improve patient compliance and also alleviate or avoid partial adverse drug reactions;
(3) The technological preparation process of the research is simple, easy and reasonable to prepare, and stable in performance, and creates conditions for realizing industrial productization.
Detailed Description
The technical scheme of the present invention will be described in detail by means of specific examples, which should be explicitly set forth for illustration, but should not be construed as limiting the scope of the present invention.
The parameters of partial raw materials in the embodiment of the invention are as follows:
sulfuric acid, 0.1mol/L aqueous solution, product number: 68279, merck.
Levosalbutamol hydrochloride, product number: PHR3457, merck.
97% by weight of 3, 3-dithiodipropionic acid, product number: t30201 merck.
Phosphate buffer, ph=7.2-7.4, with armed pramipexole.
D, L-lactic acid with purity of 90 percent, shanghai Haohong biological medicine technology.
Polylactic acid-glycolic acid copolymer (50:50), molecular weight: 10000-20000, purity not less than 99wt%, purchased from MedChemexpress.
Comparative example 1
A preparation method of a levalbuterol hydrochloride aerosol inhalation solution comprises the following steps:
s1, adding 2L of purified water into a liquid distributor, adding 0.73g of levosalbutamol hydrochloride and 27g of sodium chloride, and stirring until the mixture is completely dissolved;
s2, adding sulfuric acid to adjust the pH to 5.3;
s3, adding purified water to 3L, and stirring to uniformly mix the purified water;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into an ampoule with the filling amount of 3mL.
Example 1
A preparation method of a levalbuterol hydrochloride aerosol inhalation solution sustained release agent comprises the following steps:
s1, adding 2L of purified water into a liquid distributor, adding 4g of levalbuterol hydrochloride composite nano particles and 27g of sodium chloride, and stirring until the nano particles are completely dissolved;
s2, adding sulfuric acid to adjust the pH to 5.3;
s3, adding purified water to 3L, and stirring to uniformly mix the purified water;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into an ampoule with the filling amount of 3mL.
The preparation method of the levalbuterol hydrochloride composite nano-particles comprises the following steps:
x1, weighing 6g of levosalbutamol hydrochloride, adding the levosalbutamol hydrochloride into 60mL of dichloromethane, stirring for 2 hours, adding 0.02g of 4-dimethylaminopyridine, 0.02g of 3, 3-dithiodipropionic acid and 0.5g of N, N' -dicyclohexylcarbodiimide, heating to 40 ℃ for reflux, stirring for 3 days, filtering after the reaction is finished, and drying a filter cake to obtain levosalbutamol hydrochloride dimer;
x2, weighing 0.65g of D, L-lactic acid, 0.30g of ethylene glycol and 0.15g of maleic acid, adding 0.03g of benzoyl peroxide and 0.01g of stannous iso-octoate into an ampoule bottle, vacuumizing the ampoule bottle, drying at 35 ℃ for 12 hours, performing melt polymerization at 140 ℃ for 24 hours, dissolving the mixture into 30mL of chloroform after the reaction is finished, adding into 100mL of ethanol, precipitating, filtering, and vacuum drying a filter cake to obtain maleic anhydride modified polylactic acid;
x3, dissolving 1g of the maleic anhydride modified polylactic acid in the step X2 in 5mL of chloroform, slowly dropwise adding 0.3g of 1, 4-butanediamine, stirring at 10 ℃ for 10min, heating to room temperature, stirring for 30min, adding the mixture into 100mL of ethanol after the reaction is finished, stirring, precipitating to generate, filtering, washing a filter cake with water to pH=7, and drying at 40 ℃ for 24h to obtain a modified poly (D, L-lactic acid-ethylene glycol) polymer;
x4 weighing 1.5g of levosalbutamol hydrochloride dimer, adding 0.125g of modified poly (D, L-lactic acid-ethylene glycol) polymer into 5mL of dimethyl sulfoxide, stirring and dissolving, adding 45mL of water, carrying out ultrasonic dispersion for 2 hours at 40kHz and 400W, continuing adding 2mg of tannic acid and 0.5mg of ferric chloride, carrying out ultrasonic dispersion for 2 hours at 40kHz and 400W, centrifuging at 10000rpm to obtain a lower precipitate, and drying at 30 ℃ for 4 hours to obtain the levosalbutamol hydrochloride composite nano-particles.
Example 2
A preparation method of a levalbuterol hydrochloride aerosol inhalation solution sustained release agent comprises the following steps:
s1, adding 2L of purified water into a liquid distributor, adding 5g of levalbuterol hydrochloride composite nano particles and 27g of sodium chloride, and stirring until the nano particles are completely dissolved;
s2, adding sulfuric acid to adjust the pH to 5.3;
s3, adding purified water to 3L, and stirring to uniformly mix the purified water;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into an ampoule with the filling amount of 3mL.
The preparation method of the levalbuterol hydrochloride composite nano-particles comprises the following steps:
x1, weighing 6g of levosalbutamol hydrochloride, adding the levosalbutamol hydrochloride into 60mL of dichloromethane, stirring for 2 hours, adding 0.02g of 4-dimethylaminopyridine, 0.02g of 3, 3-dithiodipropionic acid and 0.5g of N, N' -dicyclohexylcarbodiimide, heating to 40 ℃ for reflux, stirring for 3 days, filtering after the reaction is finished, and drying a filter cake to obtain levosalbutamol hydrochloride dimer;
x2, weighing 1.5g of levosalbutamol hydrochloride dimer, adding 0.125g of polylactic acid-glycolic acid copolymer into 5mL of dimethyl sulfoxide, stirring and dissolving, adding 45mL of water, carrying out ultrasonic dispersion for 2h at 40kHz and 400W, continuously adding 2mg of tannic acid and 0.5mg of ferric chloride, carrying out ultrasonic dispersion for 2h at 40kHz and 400W, centrifuging at 10000rpm to obtain a lower precipitate, and drying at 30 ℃ for 4h to obtain the levosalbutamol hydrochloride composite nano-particles.
Example 3
A preparation method of a levalbuterol hydrochloride aerosol inhalation solution sustained release agent comprises the following steps:
s1, adding 2L of purified water into a liquid distributor, adding 4g of levosalbutamol hydrochloride liposome particles and 27g of sodium chloride, and stirring until the mixture is completely dissolved;
s2, adding sulfuric acid to adjust the pH to 5.3;
s3, adding purified water to 3L, and stirring to uniformly mix the purified water;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into an ampoule with the filling amount of 3mL.
The preparation method of the levosalbutamol hydrochloride liposome particles comprises the following steps:
x1, weighing 8g of lecithin, 24g of cholesterol, 4g of levosalbutamol hydrochloride, adding 100mL of acetone for dissolution, then rotationally evaporating a spin-drying solvent, and then adding phosphate buffer for hydration of 500mL to obtain a suspension;
x2 the suspension in the step X1 is subjected to ultrasonic treatment for 30min under ice bath condition at 40kHz and 400W, and is subjected to spray drying after being filtered by a microporous filter membrane with the thickness of 0.8 mu m, the temperature is controlled at 35 ℃, the pressure is 0.4MPa, and the drying is carried out for 24h, so as to obtain the levosalbutamol hydrochloride liposome particles.
Test example 1
In vitro release test is carried out on the levalbuterol hydrochloride aerosol inhalation solution sustained release agent prepared in the comparative example and the example, the specific experimental method is that the prepared levalbuterol hydrochloride aerosol inhalation solution sustained release agent is put in a dialysis bag and put in a PBS (pH=7.4) solution with the temperature of 37 ℃, and the release amount of the levalbuterol hydrochloride is sampled and detected at a specific time point, so that the sustained release effect of the levalbuterol hydrochloride after encapsulation is examined. Three batches were taken in parallel for each group, and the drug loading of each batch was measured, and the final results were averaged. Taking out 2mL of 3 batches of prepared levalbuterol hydrochloride aerosol inhalation solution sustained release agents respectively, respectively placing the two batches of prepared levalbuterol hydrochloride aerosol inhalation solution sustained release agents in 3 clean and leak-free dialysis bags, binding the two ends of the dialysis bags by ropes, and carefully checking whether the leakage phenomenon exists. 50mL of PBS buffer (pH=7.40) was precisely measured in volumetric flasks and placed in 3 clean 100mL flasks, respectively, and heated in a water bath on a hot plate of a magnetic stirrer, set at 37℃and a rotational speed of 50rpm. After the PBS buffer in the bottle had been kept at 37℃the dialysis bags were placed in the bottles, respectively, and the timing was started immediately, 1mL of sample in the bottle was taken at the following time points (0.5 h, 2h, 8h, 35h, 120h, 192 h) and 1mL of PBS was added. 3 batches of release samples were centrifuged at 13000rpm for 5 minutes and 800. Mu.L of supernatant was taken for detection by liquid chromatograph, the detected release being the cumulative release after this time.
The specific test results are shown in Table 1.
TABLE 1 in vitro Release test
In vitro release test studies were performed to verify the effect of the hypothesis that levosalbutamol hydrochloride after encapsulation could produce sustained release under in vitro physiological conditions. As can be seen from the results of the in vitro release test, the levosalbutamol hydrochloride in comparative example 1 is not encapsulated, 90.8% of the levosalbutamol hydrochloride is released in 8 hours, and the levosalbutamol hydrochloride encapsulates in examples 1 to 3 are completely released, and the levosalbutamol hydrochloride composite nanoparticle in example 1 has the best sustained-release effect, which is probably due to the tight combination of tannic acid molecules and iron ions to form a composite network, and the levosalbutamol hydrochloride dimer is complexed in the composite network, so that the sustained-release effect is enhanced, the active ingredient can maintain a stable and long-acting sustained-release effect, and the stability of the complexing structure further ensures the sustained-release effect.
Test example 2
The storage stability test was performed on the levalbuterol hydrochloride aerosol inhalation solution sustained release agent prepared in the comparative example and the example, and 5 batches of samples were taken in parallel for each group, three of which were stored at 4 ℃ for 10 days, 20 days, 30 days, and the other two batches were stored at 25 ℃ for 10 days, 20 days, respectively. After expiration of storage under different temperature conditions, 100 μl was sampled for detection of encapsulation efficiency. The specific test results are shown in Table 2.
Table 2 storage stability test results table
As can be seen from the storage stability test, the stability of examples 1 and 2 in examples 1 to 3 is obviously better than that in example 3, the encapsulation of the levosalbutamol hydrochloride liposome in example 3 is more stable under the low temperature condition, the encapsulation rate can still ensure a certain encapsulation rate after long-term preservation, but phospholipid and cholesterol encapsulated on the surface of the liposome are likely to be degraded when the temperature is higher, so that effective substances in the liposome leak, and in example 1, the prepared modified poly (D, L-lactic acid-ethylene glycol) polymer is used for encapsulating active substances, the water solubility is enhanced, meanwhile, the stability is improved, and the tight combination of tannic acid molecules and iron ions forms a composite network, and the levosalbutamol hydrochloride dimer is better in stability and can be ensured not to leak the effective components under the condition of higher temperature.
Test example 3
In-vivo efficacy experiments are carried out on the levalbuterol hydrochloride aerosol inhalation solution sustained release agent prepared in the comparative example and the example, the animals used in the experiments are ordinary albino guinea pigs which are purchased from animal experiment centers of university of south medical science, the male and female parts are half, the weight is 290+/-40 g, a proper amount of water and food are added to feed the animals in an environment with the temperature of 25+/-2 ℃ and the humidity of 60+/-5%, and the animals are alternately irradiated for 12 hours. Sequentially placing guinea pigs into a 4-liter sealed bell jar of a multifunctional cough and asthma inducing instrument, atomizing 0.6% histamine solution (prepared by physiological saline) into the sealed bell jar at an atomization speed of 0.15mL/min by using an ultrasonic atomizer for 15s, stopping atomization, and observing the asthma inducing latency of the guinea pigs, namely, the time from the start of atomization to the occurrence of asthma symptoms and dyspnea of the guinea pigs, which is the period from the occurrence of convulsion and fall, discarding the time when the latency exceeds 2min, and taking a free diet and drinking water by the screened guinea pigs, so that the animals to be tested are fasted one day before the experiment. The screened guinea pigs were weighed, the uratame solution was anesthetized by intraperitoneal injection at an amount of 1.25g/kg, after about half an hour of complete anesthesia, the abdomen of the guinea pigs were fixed with the limbs and head up, then the neck skin was carefully dissected, jugular vein cannulation (cannula required to be rinsed with 0.1% heparin sodium solution and filled in the tube) and tracheal cannulation were performed, three guinea pigs were taken per group, and all experimental results were averaged. The tracheal cannula extends out of the tracing box through a hole pipe with the same diameter on the wall of the tracing box and is connected with a flow head with the diameter of 1L for measuring the respiratory flow rate; and then an intrathoracic cannula is inserted between the fourth rib bone and the fifth rib bone of the right chest of the guinea pig, and the intrathoracic cannula is connected to a pressure transducer through a conduit from an opening at the side edge of the tracing box, so that the intrathoracic pressure, the respiratory flow rate change and the tidal volume can be recorded. And (3) 15 mug/mL of histamine is intravenously injected at a speed of 1mL/min to obtain 0.5mL of histamine, the physiological state of the animal is observed, at the moment, the animal can generate symptoms of dyspnea, the change of indexes such as small tidal volume, increased intrathoracic pressure, reduced respiratory flow rate, increased respiratory frequency and the like can be seen in the recorded parameters, after the intravenous stimulation is finished, the parameters are continuously recorded, and after the animal state is stable (about 15-30 min), the steps of administration and stimulation are started. Evacuating the flow head connected to the wall of the tracing box, connecting the spray head of the compression atomizer to connect the spray head with the trachea cannula, atomizing and inhaling 1mg/mL of levosalbutamol hydrochloride atomized inhalation solution slow release agent for 2min for animals, evacuating the drug administration device, reconnecting the flow head with the exported trachea cannula, after the animals are stabilized for about 4min, injecting 15 mug/mL of histamine for 0.5mL intravenously, observing the change of parameters, waiting for the stable state of the animals, and continuing recording the parameters. After 4 hours of administration, 15. Mu.g/mL histamine was intravenously injected 0.5mL, the change of the parameters was observed, the animal was waited for stable status, and the parameters were continuously recorded for about 5 minutes. The above values are calculated according to the airway resistance=the variation value of the intrathoracic pressure/the variation value of the respiratory flow rate, the dynamic lung compliance=the tidal volume/the variation value of the intrathoracic pressure, the above values after administration and before administration are subtracted and divided by the values before administration, and the variation rates of the two parameters are obtained, and the specific experimental results are shown in table 3.
TABLE 3 in vivo results of drug efficacy experiments
The guinea pig asthma model is more suitable than the rat or mouse as a human airway pharmacological model; in this experiment, histamine phosphate was used to induce airway hyperresponsiveness in guinea pigs to establish an asthma model, which works on the principle of causing bronchosmooth muscle contraction by agonizing the H1 receptor. Guinea pigs are extremely sensitive to histamine, can be rapidly molded, and quickly recover normal breath after histamine stimulation is stopped, so that the guinea pigs are a commonly used rapid type bronchoconstriction model. The pathogenesis of the model is similar to that of human asthma, and the model belongs to type I allergy, and can well simulate the acute attack symptoms of human asthma, such as shortness of breath, wheezing, dyspnea and the like. The most main respiratory mechanics physiological indexes for determining lung function at present are as follows: airway resistance and dynamic lung compliance. Airway resistance refers to the pressure differential created per unit flow in the airway, expressed as the pressure differential created per minute ventilation. Dynamic lung compliance refers to the change in lung volume caused by a change in unit pressure, and represents the effect of changes in chest pressure on lung volume, the results of which can be used clinically to initially assess the patient's lung function. The combination of the two indexes can well reflect the ventilation function of the airway, compared with a blank control group, the control and the examples show obvious reduction of the rise rate of the airway resistance after administration, and the dynamic lung compliance reduction rate is obviously increased, which indicates that the asthma of guinea pigs is obviously relieved after atomization, but the asthma relieving effects of different groups are changed after the time is prolonged, the asthma relieving effect of the control example 1 is obviously poor, the example 1 is better, which is probably caused by the excellent stability and the long-acting slow release effect of the levalbuterol hydrochloride composite nano particles, and the experiment well proves that the prepared levalbuterol hydrochloride atomization inhalation solution slow release agent can last longer for relieving the asthma.
Claims (7)
1. The levosalbutamol hydrochloride aerosol inhalation solution sustained release agent is characterized by comprising the following components in percentage by mass: 0.05-0.06% of levalbuterol hydrochloride composite nano particles, 0.2-0.9% of isotonic agent, 0.001-0.005% of pH regulator and the balance of solvent; the isotonic agent is sodium chloride; the pH regulator is sulfuric acid;
the preparation method of the levalbuterol hydrochloride composite nano-particles comprises the following steps:
weighing 6-7 g of levosalbutamol hydrochloride by X1, adding the levosalbutamol hydrochloride into 60-70 mL of dichloromethane, stirring for 1-2 hours, adding 0.02-0.03 g of 4-dimethylaminopyridine, 0.02-0.03 g of 3, 3-dithiodipropionic acid, 0.5-0.6 g of N, N' -dicyclohexylcarbodiimide, heating to 40-45 ℃ for reflux, stirring for 2-3 days, filtering after the reaction is finished, and drying a filter cake to obtain levosalbutamol hydrochloride dimer;
weighing 0.63-0.65 g of D, L-lactic acid, 0.27-0.30 g of ethylene glycol, 0.1-0.15 g of maleic acid, adding 0.3-0.04 g of benzoyl peroxide and 0.01-0.02 g of stannous octoate into an ampoule bottle, vacuumizing the ampoule bottle, drying at 30-35 ℃ for 10-12 h, performing melt polymerization at 140-150 ℃ for 20-24 h, dissolving the mixture into 20-30 mL of chloroform after the reaction is finished, adding into 100-200 mL of ethanol, precipitating, filtering, and performing vacuum drying on a filter cake to obtain maleic anhydride modified polylactic acid;
x3, dissolving 1-1.1 g of the maleic anhydride modified polylactic acid in the step X2 in 5-10 mL of chloroform, slowly dropwise adding 0.2-0.3 g of 1, 4-butanediamine, stirring for 10-20 min at 5-10 ℃, heating to room temperature, stirring for 30-40 min, adding the mixture into 50-100 mL of ethanol after the reaction is finished, stirring, precipitating, filtering, washing a filter cake with water until the pH value is 7-8, and drying at 35-40 ℃ for 20-24 h to obtain a modified poly (D, L-lactic acid-ethylene glycol) polymer;
and X4, weighing 1.5g of levosalbutamol hydrochloride dimer, adding 0.125g of modified poly (D, L-lactic acid-ethylene glycol) polymer into 5-6 mL of dimethyl sulfoxide, stirring and dissolving, adding 45-54 mL of water, performing ultrasonic dispersion for 1-2 h, continuously adding 2mg of tannic acid and 0.5mg of ferric chloride, performing ultrasonic dispersion for 1-2 h, centrifuging at 8000-10000 rpm, obtaining lower-layer sediment, and drying to obtain the levosalbutamol hydrochloride composite nano particles.
2. A method for preparing the aerosol inhalation solution slow release formulation of claim 1, comprising the steps of:
s1, adding 50-80% of the total amount of solvent into a liquid dispenser, adding the prescription amount of levalbuterol hydrochloride composite nano particles and an isotonic agent, and stirring until the solvent is completely dissolved;
s2, adding a pH regulator to regulate the pH;
s3, adding the solvent to the full amount, and stirring to uniformly mix the solvent;
s4, performing primary filtration by using a 0.45 mu m filter membrane, performing fine filtration by using a 0.22 mu m filter membrane, wherein the primary filtration and the fine filtration are sterile filtration, and filling the sterile filtration into ampoule bottles with the filling amount of 3mL.
3. The method of claim 2, wherein the solvent is purified water, water for injection.
4. The method of claim 2, wherein the total amount of solvent is 3 to 4l.
5. The method of claim 2, wherein the prescription amount of the levalbuterol hydrochloride composite nanoparticle is 4-5 g.
6. The method of claim 2, wherein the isotonic agent is added in an amount of 27 to 30g.
7. The method according to claim 2, wherein the solvent stirring temperature in the step S1 is controlled to be 15-35 ℃; and the pH value adjusted in the step S2 is 4.5-5.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211287768.2A CN115645381B (en) | 2022-10-20 | 2022-10-20 | Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211287768.2A CN115645381B (en) | 2022-10-20 | 2022-10-20 | Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115645381A CN115645381A (en) | 2023-01-31 |
| CN115645381B true CN115645381B (en) | 2023-05-30 |
Family
ID=84989562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211287768.2A Active CN115645381B (en) | 2022-10-20 | 2022-10-20 | Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115645381B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3297402A (en) * | 2001-10-26 | 2003-10-30 | Dey, L.P. | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
| CN101889994A (en) * | 2010-06-01 | 2010-11-24 | 中国药科大学 | Salbutamol sulfate sustained-release aerosol of micropowder for inspiration and preparation method thereof |
| US11648261B2 (en) * | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| CN113476428B (en) * | 2021-01-28 | 2022-03-29 | 朗天药业(湖北)有限公司 | Salbutamol sulfate solution for inhalation and preparation method thereof |
| CN115154613B (en) * | 2022-07-27 | 2023-10-31 | 东北林业大学 | preparation and application of pH-sensitive nano modified hydroxyapatite/iron-tannic acid |
-
2022
- 2022-10-20 CN CN202211287768.2A patent/CN115645381B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| C P Neal等.Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.《full text links full text provider logo actions Cite Collections share page navigation Title & authors Abstract Similar articles Cited by Publication types MeSH terms Substances Related information LinkOut - more resources FEMS Microbiol Lett .》.2001,第194卷(第2期),第163-169页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115645381A (en) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2429497B1 (en) | Process for preparing microparticles | |
| JP4990142B2 (en) | Diketopiperazine salt, diketomorpholine salt, or diketodioxane salt for drug delivery | |
| ES2643182T3 (en) | Artemisinin and derivatives for use in the treatment of trauma hemorrhage | |
| CN112716936B (en) | Preparation method of puerarin nanoparticles | |
| WO2004039381A1 (en) | Adsorbents for oral administration, remedies or preventives for kidney diseases and remedies or preventives for liver diseases | |
| PT1531798E (en) | Pulmonary delivery for levodopa | |
| EP3932400B1 (en) | Peramivir solution type inhalant and preparation method therefor | |
| CN108904489A (en) | The purposes of the preventing respiratory diseases associated with inflammation of 3,4 ' flavonol of 5,7- methoxyl group | |
| EP3730133A1 (en) | Fudosteine solution preparation for aerosol inhalation, and preparation method therefor | |
| CN112168975A (en) | Anti-tumor targeted drug sustained-release carrier, preparation and preparation method thereof | |
| CN115645381B (en) | Levalmol hydrochloride aerosol inhalation solution sustained release agent and preparation method thereof | |
| Guan et al. | Applications of chitosan in pulmonary drug delivery | |
| CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
| JP2002542209A (en) | Formulation for detecting asthma | |
| CN114344380A (en) | Asthma-relieving aerosol inhalation solution preparation and preparation method thereof | |
| CN109674763B (en) | Monoamine oxidase responsive salidroside/mesoporous silicon nano brain targeted controlled release system | |
| CN112957350A (en) | A herba Houttuyniae aerosol inhalation solution and its preparation method | |
| CN106806418A (en) | A kind of swap buffers Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN114948914B (en) | Moxifloxacin hydrochloride solution for aerosol inhalation and preparation method thereof | |
| CN114886878B (en) | 18 beta-glycyrrhetinic acid liposome and preparation method and application thereof | |
| CN114732789B (en) | Compound long-acting drug delivery system for treating pulmonary hypertension and preparation thereof | |
| CN115137713B (en) | Amphotericin B aerosol inhalation preparation and preparation method thereof | |
| Kulkarni et al. | Design and characterization of zanamivir loaded niosomes | |
| CN114632072B (en) | Preparation and application of ginsenoside Rg5 lipid nanoparticle sustained release preparation | |
| CN111700883B (en) | Salbutamol sulfate sustained-release inhalation preparation and production process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |